Kaplan-Meier estimates of PSA progression-free survival probability for the 77 patients with clinically localized PCa treated with RP, who were grouped by the baseline serum EPCA level above or below the median value of 15.20 ng/ml.

<p>Kaplan-Meier estimates of PSA progression-free survival probability for the 77 patients with clinically localized PCa treated with RP, who were grouped by the baseline serum EPCA level above or below the median value of 15.20 ng/ml.</p

Clinical and Pathologic Features of 128 Patients with PCa.

<p>Clinical and Pathologic Features of 128 Patients with PCa.</p

Univariate and multivariate Cox regression analyses of pre-operative variables for the prediction of biochemical progression after RP for 77 patients with clinically localized PCa.

<p>*Initial PSA levels were categorized as ≥10 ng/ml versus <10 ng/ml.</p>†<p>Clinical stage was categorized as T1 versus T2.</p>‡<p>Gleason score was categorized as grade 2 to 6 versus grade 7 to 10.</p>§<p>p<0.05, statistically significant.</p

Baseline serum levels of EPCA in healthy controls and PCa patients and association of EPCA levels with clinicopathological variables in 128 prostatic carcinomas.

∥<p>Categorized by the median value.</p><p>*Mann-Whitney U test.</p>†<p>Kruskal-Wallis test.</p>‡<p>Including lymph node metastases and distant metastases to bone and liver.</p>§<p>p<0.05, statistically significant.</p

Kaplan-Meier estimates of AIP-free survival probability for the 51 patients with locally advanced and metastatic PCa treated with ADT, who were grouped by the baseline serum EPCA level above or below the median value of 15.20 ng/ml.

<p>Kaplan-Meier estimates of AIP-free survival probability for the 51 patients with locally advanced and metastatic PCa treated with ADT, who were grouped by the baseline serum EPCA level above or below the median value of 15.20 ng/ml.</p